Abstract
Fifty subjects at risk of herpes genitalis received 109 immunizations with Skinner herpes vaccine and were assessed after a follow-up period of 4–48 months, respresenting a total follow-up period of 694 patient months. There was no evidence of contraction of herpes genitalis in 49 subjects. The risk of virus transmission and rate of contraction of disease was quantified by construction of two functions, namely a unit of exposure risk calculated per year (UYE) and standard contraction rate (SCR); in this study the SCR was 0.02. There was no evidence of significant side-effects from vaccination. Administration of Alhydrogel adjuvant with vaccine induced temporary granuloma formation in most subjects but was only detectable beyond 1 year of follow-up in one subject, in whom a painless swelling of 0.2 cm was detected 3 years after vaccination. There was no evidence of immunological reactivity to host cell or calf serum antigens in any of the subjects vaccinated.
Similar content being viewed by others
References
Asher LVS, Walz MA, Notkins AB (1978) Effect of immunisation on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2. Am J Obstet Gynecol 131:788–789
Cappel R, Sprencher S, de Cuyper F (1982) Immune responses to DNA free herpes simplex proteins in Man. Arch Virol 73:61
Carter CA, Hartley CE, Skinner GRB, Turner SP, Easty DL (1981) Preliminary observations on the efficacy of a herpes simplex virus sub-unit vaccine. Br J Ophthalmol 65:679–685
Chen Min-Hui, Dong Chang-Yuan, Liu Zhi-Hui, Skinner GRB, Hartley CE (1983) Prevention of type 2 herpes simplex virus induced cervical carcinoma in mice by prior immunization with a vaccine prepared from type 1 herpes simplex virus. Vaccine 1:13–15
Howes EL, Clarke EA, Smith E, Mitchison NA (1979) Mouse hybrid cell lines produced antibodies to herpes simplex virus type 1. J Gen Virol 44:81–87
Lipschütz B (1927) Untersuchungen über die Etiologie der Krankheiten der Herpesgruppe. Arch Dermatol Syphilol 136:428–431
McKendall RR (1977) Efficacy of herpes simplex virus type 1 immunisation in protecting against acute and latent infection by herpes simplex virus type 2 in mice. Infect Immun 16:717–719
Mertz GJ, Schmidt O, Jourden JL, Guinan ME, Remington ML, Fahnlander A, Winter C, Holmes KK, Corey L (1985) Frequency of acquisition of first-episode genital infection and herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 12:33–39
Skinner GRB, Williams DR, Buchan A, Whitney J, Harding M, Bodfish K (1978) Preparation and efficacy of an inactivated subunit vaccine (NFU1 BHK) against type 2 herpes simplex virus infection. Med Microbiol Immunol 166:119–132
Skinner GRB, Woodman CBJ, Hartley CE, Buchan A, Fuller A, Durham J, Synnott M, Clay JC, Melling J, Wiblin C, Wilkins J 91982) Preparation and immunogenicity of vaccine Ac NFU1 (S−) MRC towards the prevention of herpes genitalis. Br J Vener Dis 58:381–386
Skinner GRB, Buchan A, Williams D, Marsden J, Hartley CE, Wilbanks G, Turyk M, Namkoong ES (1982) Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFU1 (S−) MRC against primary type 2 herpes simplex virus infection. Br J Exp Pathol 63:378–387
Sturn B, Schneweis K (1978) Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2. Med Microbiol Immunol 165:119–127
Wentz WB, Heggie AD, Anthony DD, Reagan JW (1983) Effect of prior immunisation on induction of cervical cancer in mice by herpes simplex virus type 2. Science 222:1128–1129
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skinner, G.R.B., Fink, C.G., Cowan, M. et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol 176, 161–168 (1987). https://doi.org/10.1007/BF00193897
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00193897